USA |NASDAQ |USD
| Report Date | Period Ending | EPS Forecast | Last Quarter's EPS | Last Year's EPS |
|---|---|---|---|---|
| Nov 3, 2021 | Sep 2021 | $-0.89 | $-0.66 | $-0.98 |
| Report Date | Period Ending | Revenue Forecast | Last Quarter’s Revenue | Last Year’s Revenue |
|---|---|---|---|---|
| Nov 3, 2021 | Sep 2021 | $18.74M | $54.02M | $8.13M |
Bridgebio Pharma, Inc's next earnings date is Wednesday, Nov 3, 2021 for the fiscal quarter ending Sep 2021.
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2021 | 8 | $-0.91 | $-1.18 | $-0.68 |
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2021 | 8 | $-3.65 | $-4.11 | $-3.26 |
| Dec 2022 | 8 | $-3.67 | $-5.03 | $-2.69 |
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|---|---|---|---|
| Dec 2021 | 0 / 1 | $-0.90 | $-0.90 | $-1.00 |
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|---|---|---|---|
| Dec 2021 | 1 / 1 | $-3.67 | $-3.68 | $-3.94 |
| Dec 2022 | 1 / 2 | $-3.58 | $-3.53 | $-3.98 |
| Period End | # of Analysts | Revenue Forecast | Low Revenue Forecast | High Revenue Forecast |
|---|---|---|---|---|
| Dec 2021 | 8 | $30.91M | $1.19M | $103.34M |
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2021 | 7 | $110.40M | $56.87M | $209.23M |
| Dec 2022 | 8 | $115.99M | $18.52M | $316.75M |
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| Nov 3, 2021 | Sep 2021 | $-0.89 | - | - |
| Aug 5, 2021 | Jun 2021 | $-0.97 | $-0.66 | 32.11% |
| May 6, 2021 | Mar 2021 | $-0.81 | $-1.18 | -45.27% |
| Feb 25, 2021 | Dec 2020 | $-0.85 | $-1.01 | -19.29% |
| Nov 5, 2020 | Sep 2020 | $-0.97 | $-0.98 | -0.68% |
| Aug 11, 2020 | Jun 2020 | $-0.80 | $-1.03 | -28.40% |
| May 13, 2020 | Mar 2020 | $-0.71 | $-0.78 | -9.14% |
| Mar 2, 2020 | Dec 2019 | $-0.71 | $-0.62 | 12.22% |
| Nov 7, 2019 | Sep 2019 | $-0.55 | $-0.51 | 7.73% |
| Aug 14, 2019 | Jun 2019 | $-0.55 | $-0.56 | -1.54% |
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| Feb 25, 2021 | Dec 2020 | $-3.54 | $-3.80 | - |
| Mar 2, 2020 | Dec 2019 | $-2.87 | $-1.69 | - |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| Nov 3, 2021 | Sep 2021 | $18.74M | - | - |
| Aug 5, 2021 | Jun 2021 | $34.84M | $54.02M | 1.55% |
| May 6, 2021 | Mar 2021 | $30.48M | $462.00K | 0.02% |
| Feb 25, 2021 | Dec 2020 | $16.93M | $122.00K | 0.01% |
| Nov 5, 2020 | Sep 2020 | $8.60M | $8.13M | 0.95% |
| Aug 11, 2020 | Jun 2020 | $0.00 | $0.00 | - |
| May 13, 2020 | Mar 2020 | $0.00 | $13.82M | - |
| Mar 2, 2020 | Dec 2019 | $0.00 | $13.82M | - |
| Nov 7, 2019 | Sep 2019 | $0.00 | $26.74M | - |
| Aug 14, 2019 | Jun 2019 | $0.00 | $0.00 | - |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| Feb 25, 2021 | Dec 2020 | $24.13M | $8.25M | -65.81% |
| Mar 2, 2020 | Dec 2019 | $0.00 | $40.56M | - |
BBIO's next earnings date is Wednesday, Nov 3, 2021 for the fiscal quarter ending Sep 30, 2021.
According to 8 analysts, the average EPS estimation for Bridgebio Pharma, Inc's next quarterly earnings is $-0.89, with a low EPS estimation of $-1.10, and a high estimation of $-0.67.
Over the last 1 month, EPS estimates have seen 0 upward revisions and 2 downward. The EPS 1 month trend is $-0.87, the last 2 month trend is $-0.86, and the 3 month trend is $-0.88.
Based on 6 analysts, the average revenue estimation is $18.74M, with a low revenue estimation of $500.00K, and a high estimation of $51.40M.
Bridgebio Pharma, Inc's previous earnings date was Aug 5, 2021 for its fiscal quarter ended Jun 30, 2021.
BBIO's earnings per share (EPS) was $-0.66, beating the consensus analysts forecast of $-0.97 by 32.11%.
The EPS was higher than the previous fiscal quarter (Mar 2021) by -44.07%, and higher than the same period a year before (Jun 2020) by -35.92%.
Revenues were $54.02M.
The company reported a net income of $-96.35M.Free cash flow for the quarter was $-94.00M , compared to $-152.73M last quarter and $-88.19M a year before.
BBIO ended the quarter with $1.40B in total debt, an increase of 1.01% compared to the previous quarter, and an increase of 82.17% compared to the same quarter a year before.
Bridgebio Pharma, Inc's previous annual earnings date was Feb 25, 2021 for its fiscal year ended Dec 31, 2020.
BBIO's earnings per share (EPS) was $-3.80, missing the consensus analysts forecast of $-3.54 by 7.34% , and lower than the previous year's EPS (Dec 2019) by 124.85%.
Revenues were $8.25M, worse than the forecast of $24.13M by -65.81%, and down by -79.66% from previous year's revenue.
The company reported a net income of $-448.72M.
Bridgebio Pharma, Inc reported a free cash flow of $-407.23M for its fiscal year, compared to $-258.73M a year ago.
The company ended the fiscal year with $481.11M in total debt, an increase of 382.12% compared to the previous year.
Get a weekly snapshot of one new investment idea from stock exchanges worldwide.
